Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers

Background Radiofrequency ablation (RFA) is minimally invasive and can achieve a high rate of cure of liver cancer. This study was conducted to evaluate the efficacy and safety of a bipolar RFA device (CelonPOWER System) in the treatment of Japanese liver cancer patients. Methods The study was a mul...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology 2013-07, Vol.48 (7), p.874-883
Main Authors: Osaki, Yukio, Ikeda, Kenji, Izumi, Namiki, Yamashita, Satoyoshi, Kumada, Hiromitsu, Hatta, Shinji, Okita, Kiwamu
Format: Article
Language:English
Subjects:
Abdominal Surgery
Ablation (Surgery)
Adult
Aged
Aged, 80 and over
Biliary Tract
Cancer
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - surgery
Care and treatment
Catheter Ablation - adverse effects
Catheter Ablation - methods
Colorectal Surgery
Female
Follow-Up Studies
Gastroenterology
Hepatology
Humans
Japan
Liver cancer
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology, Experimental
Original Article—Liver
Pancreas
Practice Guidelines as Topic
Prospective Studies
Surgical Oncology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Radiofrequency ablation (RFA) is minimally invasive and can achieve a high rate of cure of liver cancer. This study was conducted to evaluate the efficacy and safety of a bipolar RFA device (CelonPOWER System) in the treatment of Japanese liver cancer patients. Methods The study was a multicenter, single-group, open-label trial. The indications for RFA were based on the Japanese guidelines for the management of liver cancer. The subjects had a Child-Pugh classification of A or B, and the target tumors were defined as nodular, numbering up to 3 lesions, each of which was 3 cm or less in diameter, or solitary lesions up to 4 cm in diameter. To test for the non-inferiority of the CelonPOWER System, this system was compared with the Cool-tip RF System, which has already been approved in Japan, in terms of the complete necrosis rate (CNR). Results The CNR obtained with the CelonPOWER System was 97.8 % (88/90 patients). The CNR obtained with the Cool-tip RF System was 86.2 % (50/58 patients), confirming the non-inferiority of the CelonPOWER System ( p  
ISSN:0944-1174
1435-5922
DOI:10.1007/s00535-012-0685-x